美国类风湿关节炎相关医疗照护费用:系统文献综述与荟萃分析
该系统综述与荟萃分析纳入12篇研究,评估美国类风湿关节炎(RA)患者直接医疗费用。所有接受任一治疗方案的RA患者总直接医疗费用为12509美元(95%CI 7451-21001),生物改善病情抗风湿药(bDMARD)使用者为36053美元(95%CI 32138-40445);RA相关费用分别为3723美元(95%CI 2408-5762)和20262美元(95%CI 17480-23487)。
要点
- 所有接受任一治疗方案的RA患者总直接医疗费用为12509美元(95%CI 7451-21001)。
- bDMARD使用者总直接医疗费用为36053美元(95%CI 32138-40445)。
- bDMARD使用者RA相关费用占总直接医疗费用的一半以上。
核心结论
- RA患者的总直接医疗费用和疾病特异性直接医疗费用均相当可观。
- 在bDMARD使用者中,RA照护费用占所有直接医疗费用的一半以上。
研究设计与样本
- 研究类型为系统文献综述与荟萃分析,检索范围限定为美国境内、自首个bDMARD上市以来的RA患者直接医疗费用研究。
- 采用标准检索策略与来源,由2名评价者独立提取数据,并评估纳入研究的方法学与质量。
- 共发现541篇可能相关研究,最终12篇文章符合入选标准。
- 纳入研究质量参差不齐:三分之一为差、三分之一为一般、三分之一为良好。
- 采用随机效应荟萃分析计算总直接医疗费用及RA相关费用,预设亚组包括Medicare患者和bDMARD使用者。
主要发现
- 所有接受任一治疗方案的RA患者总直接医疗费用为12509美元(95%CI 7451-21001)。
- bDMARD使用者总直接医疗费用为36053美元(95%CI 32138-40445)。
- 所有接受任一治疗方案的RA患者RA相关费用为3723美元(95%CI 2408-5762)。
- bDMARD使用者RA相关费用为20262美元(95%CI 17480-23487)。
关键数值与推荐
- 所有接受任一治疗方案的RA患者总直接医疗费用:12509美元(95%CI 7451-21001)。
- bDMARD使用者总直接医疗费用:36053美元(95%CI 32138-40445)。
- 所有接受任一治疗方案的RA患者RA相关费用:3723美元(95%CI 2408-5762)。
- bDMARD使用者RA相关费用:20262美元(95%CI 17480-23487)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 纳入研究的质量参差不齐:三分之一为差、三分之一为一般、三分之一为良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Rheumatoid arthritis (RA) is a morbid, mortal, and costly condition without a cure. Treatments for RA have expanded over the last 2 decades, and direct medical costs may differ by types of treatments. There has not been a systematic literature review since the introduction of new RA treatments, including biologic disease-modifying antirheumatic drugs (bDMARDs). METHODS: We conducted a systematic literature review with meta-analysis of direct medical costs associated with RA patients cared for in the US since the marketing of the first bDMARD. Standard search strategies and sources were used, and data were extracted independently by 2 reviewers. The methods and quality of included studies were assessed. Total direct medical costs as well as RA-specific costs were calculated using random-effects meta-analysis. Subgroups of interest included Medicare patients and those using bDMARDs. RESULTS: We found 541 potentially relevant studies, and 12 articles met the selection criteria. The quality of studies varied: one-third were poor, one-third were fair, and one-third were good. Total direct medical costs were estimated at $12,509 (95% confidence interval [95% CI] 7,451-21,001) for all RA patients using any treatment regimen and $36,053 (95% CI 32,138-40,445) for bDMARD users. RA-specific costs were $3,723 (95% CI 2,408-5,762) for all RA patients using any treatment regimen and $20,262 (95% CI 17,480-23,487) for bDMARD users. CONCLUSION: The total and disease-specific direct medical costs for patients with RA is substantial. Among bDMARD users, the cost of RA care is more than half of all direct medical costs.
引用
- Hresko A, Lin TC, Solomon DH, et al. Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2018. PMID: 29316377. doi:10.1002/acr.23512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。